“off” time

Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson’s Disease

By Emmanuelle Pourcher MD, DEM and Philippe Huot MD, PhD*

Treatment of motor fluctuations in Parkinson’s disease (PD) remains an unmet challenge. Adenosine 2A (A2A) receptors are located along the indirect pathway and represent a potential target to enhance L-3,4-dihydroxyphenylalanine (L-DOPA) antiparkinsonian action.

Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results

By Hubert H. Fernandez MD*, David G. Standaert MD, PhD*, Robert A. Hauser MD, Anthony E. Lang MD, FRCPC, Victor S.C. Fung PhD, FRACP, Fabian Klostermann PhD, Mark F. Lew MD, Per Odin MD, PhD, Malcolm Steiger MBBS, MD, FRCP, Eduard Z. Yakupov MD, PhD, DMSc, Sylvain Chouinard MD, FRCPC, Oksana Suchowersky MD, FRCPC, FCCMG, Jordan Dubow MD, Coleen M. Hall MS, Krai Chatamra PhD, Weining Z. Robieson PhD, Janet A. Benesh BSMT and Alberto J. Espay MD, MSc

Motor complications in Parkinson’s disease (PD) are associated with long-term oral levodopa treatment and linked to pulsatile dopaminergic stimulation. L-dopa-carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG-J), which reduces L-dopa-plasma–level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54-week, open-label LCIG study…

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease

By Stewart A. Factor DO*, Kenneth Wolski MD, Daniel M. Togasaki MD, PhD, Susan Huyck DrPH, Marc Cantillon MD†, T.W. Ho MD‡, Robert A. Hauser MD, MBA and Emmanuelle Pourcher MD

Preladenant is a selective adenosine A2A receptor antagonist under investigation for Parkinson’s disease treatment.

“off” time

Footer